SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                         Date of Report: August 18, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                   Delaware                         52-1555759
          (State of Incorporation)      (I.R.S. Employer Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.



<PAGE>


MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated August 17, 1999:


          MEDIMMUNE APPOINTS ARMANDO ANIDO, R.PH. SENIOR VICE PRESIDENT
                             OF SALES AND MARKETING

Gaithersburg,  MD,  August 17,  1999 --  MedImmune,  Inc.  (Nasdaq:  MEDI) today
announced  that  Armando  Anido,  R.Ph.  has joined the  Company as Senior  Vice
President  of Sales and  Marketing.  Mr.  Anido will  report to Melvin D. Booth,
President and Chief Operating Officer of MedImmune,  and will be responsible for
all  aspects  of the  Company's  sales  and  marketing  organization,  including
oversight of the sales force,  development  of novel  marketing  strategies  and
medical affairs.  Mr. Anido was most recently Vice President of CNS Marketing at
Glaxo Wellcome,  Inc. (NYSE:  GLX) and prior to that served six years at Lederle
Laboratories, including as Vice President of Anti-Infectives Marketing.

"As  MedImmune  continues  its exciting  growth phase and enters into the second
season  launch  of  Synagis,  it is  essential  that  the  sales  and  marketing
organization  continues  its high  level of  performance,"  commented  Melvin D.
Booth,  President and Chief Operating  Officer.  "Armando brings to MedImmune an
expertise in successfully directing the launch and development of pharmaceutical
products,  and was  instrumental  in growing the Glaxo  Wellcome CNS business by
over $950 million in two years. His experience will enhance our ability to excel
in  marketing  and  the  entrepreneurial  biotechnology  environment,  and  I am
delighted to welcome him to the Company."

While serving as Vice  President of CNS Marketing at Glaxo  Wellcome,  Mr. Anido
had profit and loss responsibility for a CNS business that exceeded $1.8 billion
in 1998. He managed the CNS marketing team and was directly  responsible for the
launches of seven products/line  extensions within 24 months.  Additionally,  he
directed the launch of Epivir (R), a  successful  HIV product with sales of over
$260 million in the first year. Prior to joining Glaxo Wellcome, Inc., Mr. Anido
served  in  various  positions  at  Lederle  Laboratories  from  1989  to  1995,
culminating in his service as the Vice President of  Anti-Infectives  Marketing.
At Lederle Laboratories, he directed the development,  launch and implementation
of two successful pharmaceutical marketing plans for ZOSYN (R), a broad spectrum
IV antibiotic and the PROSTEP (R) nicotine  patch.  From 1985 to 1989, Mr. Anido
served as the Senior Director of Marketing for Martec Pharmaceutical, Inc. Prior
to 1985, he served in various sales positions at the Upjohn  Company.  Mr. Anido
is a  registered  pharmacist,  and holds a Bachelor  of Science  and a Master of
Business Administration degree from West Virginia University.

Mr.  Anido will replace Mr. David P. Wright,  the  Executive  Vice  President of
Sales and Marketing at MedImmune, who is retiring.

"David Wright has been a key officer in building MedImmune to where it is today,
and we will  always  be  grateful  to him  for the  value  he has  added  to the
Company," said Wayne T. Hockmeyer,  Ph.D.,  Chairman and Chief Executive Officer
at MedImmune.  "Dave was directly  responsible for many of the successes we have
enjoyed at MedImmune,  including the successful launch and marketing of Synagis,
one of the most successful  pediatric  product launches in history.  His insight
and  effectiveness  as a  marketing  strategist  has been  clearly  demonstrated
throughout his career at MedImmune, and we all wish him well in his retirement."
<PAGE>

Synagis is a humanized  monoclonal  antibody which was approved for marketing in
June 1998 by the U.S. Food and Drug Administration for the prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of  RSV  disease  (please  see  full  prescribing  information  attached  or  at
http://www.medimmune.com/products/synagispi.htm).    Synagis    is   the   first
monoclonal  antibody  to be  licensed  for any  infectious  disease.  Synagis is
administered  by  intramuscular  injection  once per  month  during  anticipated
periods of RSV  prevalence  in the  community.  RSV is the most common  cause of
pneumonia and bronchiolitis in infants and children. In the Northern Hemisphere,
the RSV season  typically  commences in November and lasts  through April but it
may begin earlier or persist later in certain communities.

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.


                           MEDIMMUNE, INC.
                           (REGISTRANT)





BY (SIGNATURE)            /s/ David M. Mott
(NAME AND TITLE)          David M. Mott, Vice Chairman and
                             Chief Financial Officer
(DATE)                    August 17, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE APPOINTS ARMANDO ANIDO, R.PH. SR. V.P.", "secsgml_size_bytes": 6747}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99695443"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                         Date of Report: August 18, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                   Delaware                         52-1555759
          (State of Incorporation)      (I.R.S. Employer Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

No Exhibits are being filed with this report

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated August 17, 1999:

          MEDIMMUNE APPOINTS ARMANDO ANIDO, R.PH. SENIOR VICE PRESIDENT
                             OF SALES AND MARKETING

Gaithersburg,  MD,  August 17,  1999 --  MedImmune,  Inc.  (Nasdaq:  MEDI) today
announced  that  Armando  Anido,  R.Ph.  has joined the  Company as Senior  Vice
President  of Sales and  Marketing.  Mr.  Anido will  report to Melvin D. Booth,
President and Chief Operating Officer of MedImmune,  and will be responsible for
all  aspects  of the  Company's  sales  and  marketing  organization,  including
oversight of the sales force,  development  of novel  marketing  strategies  and
medical affairs.  Mr. Anido was most recently Vice President of CNS Marketing at
Glaxo Wellcome,  Inc. (NYSE:  GLX) and prior to that served six years at Lederle
Laboratories, including as Vice President of Anti-Infectives Marketing.

"As  MedImmune  continues  its exciting  growth phase and enters into the second
season  launch  of  Synagis,  it is  essential  that  the  sales  and  marketing
organization  continues  its high  level of  performance,"  commented  Melvin D.
Booth,  President and Chief Operating  Officer.  "Armando brings to MedImmune an
expertise in successfully directing the launch and development of pharmaceutical
products,  and was  instrumental  in growing the Glaxo  Wellcome CNS business by
over $950 million in two years. His experience will enhance our ability to excel
in  marketing  and  the  entrepreneurial  biotechnology  environment,  and  I am
delighted to welcome him to the Company."

While serving as Vice  President of CNS Marketing at Glaxo  Wellcome,  Mr. Anido
had profit and loss responsibility for a CNS business that exceeded $1.8 billion
in 1998. He managed the CNS marketing team and was directly  responsible for the
launches of seven products/line  extensions within 24 months.  Additionally,  he
directed the launch of Epivir (R), a  successful  HIV product with sales of over
$260 million in the first year. Prior to joining Glaxo Wellcome, Inc., Mr. Anido
served  in  various  positions  at  Lederle  Laboratories  from  1989  to  1995,
culminating in his service as the Vice President of  Anti-Infectives  Marketing.
At Lederle Laboratories, he directed the development,  launch and implementation
of two successful pharmaceutical marketing plans for ZOSYN (R), a broad spectrum
IV antibiotic and the PROSTEP (R) nicotine  patch.  From 1985 to 1989, Mr. Anido
served as the Senior Director of Marketing for Martec Pharmaceutical, Inc. Prior
to 1985, he served in various sales positions at the Upjohn  Company.  Mr. Anido
is a  registered  pharmacist,  and holds a Bachelor  of Science  and a Master of
Business Administration degree from West Virginia University.

Mr.  Anido will replace Mr. David P. Wright,  the  Executive  Vice  President of
Sales and Marketing at MedImmune, who is retiring.

"David Wright has been a key officer in building MedImmune to where it is today,
and we will  always  be  grateful  to him  for the  value  he has  added  to the
Company," said Wayne T. Hockmeyer,  Ph.D.,  Chairman and Chief Executive Officer
at MedImmune.  "Dave was directly  responsible for many of the successes we have
enjoyed at MedImmune,  including the successful launch and marketing of Synagis,
one of the most successful  pediatric  product launches in history.  His insight
and  effectiveness  as a  marketing  strategist  has been  clearly  demonstrated
throughout his career at MedImmune, and we all wish him well in his retirement."
Synagis is a humanized  monoclonal  antibody which was approved for marketing in
June 1998 by the U.S. Food and Drug Administration for the prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of  RSV  disease  (please  see  full  prescribing  information  attached  or  at
http://www.medimmune.com/products/synagispi.htm).    Synagis    is   the   first
monoclonal  antibody  to be  licensed  for any  infectious  disease.  Synagis is
administered  by  intramuscular  injection  once per  month  during  anticipated
periods of RSV  prevalence  in the  community.  RSV is the most common  cause of
pneumonia and bronchiolitis in infants and children. In the Northern Hemisphere,
the RSV season  typically  commences in November and lasts  through April but it
may begin earlier or persist later in certain communities.

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.

                           MEDIMMUNE, INC.
                           (REGISTRANT)

BY (SIGNATURE)            /s/ David M. Mott
(NAME AND TITLE)          David M. Mott, Vice Chairman and
                             Chief Financial Officer
(DATE)                    August 17, 1999